<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02183038</url>
  </required_header>
  <id_info>
    <org_study_id>107.193</org_study_id>
    <nct_id>NCT02183038</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Meloxicam vs. Naproxen Sodium in Patients With Acute Non Bacterial Pharyngitis or Pharyngo-tonsillitis</brief_title>
  <official_title>Double-blind Study to Compare Efficacy and Safety of Meloxicam 7.5 mg and 15 mg vs. Naproxen Sodium 1100 mg in the Symptomatic Treatment of Acute Non Bacterial Pharyngitis or Pharyngo-tonsillitis Over a Period of 5 Days</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to assess the efficacy and tolerability of Meloxicam once daily dose of 7.5 mg and 15
      mg compared with 1100 mg of naproxen sodium in the symptomatic treatment of acute non
      bacterial pharyngitis or pharyngo-tonsillitis, over a period of 5 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 1998</start_date>
  <primary_completion_date type="Actual">February 1999</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in intensity of spontaneous pharyngeal pain</measure>
    <time_frame>Baseline, day 3 and 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in intensity of pharyngeal pain on swallowing</measure>
    <time_frame>Baseline, day 3 and 5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Final global assessment of efficacy by patient</measure>
    <time_frame>Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final global assessment of efficacy by investigator</measure>
    <time_frame>Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final global assessment of tolerability by patient</measure>
    <time_frame>Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final global assessment of tolerability by investigator</measure>
    <time_frame>Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of disease systemic manifestations (fever, and general malaise)</measure>
    <time_frame>up to 5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of pharyngeal hyperemia</measure>
    <time_frame>up to 5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of patient status</measure>
    <time_frame>Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of treatment withdrawal due to lack of efficacy</measure>
    <time_frame>up to 5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of perforation, ulceration, bleeding (PUB) of the upper gastro-intestinal tract (stomach or duodenum)</measure>
    <time_frame>up to day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of adverse events</measure>
    <time_frame>up to 19 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who withdraw due to adverse event</measure>
    <time_frame>up to 19 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of significant laboratory adverse events</measure>
    <time_frame>up to 19 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence and duration of hospital stay due to Gastro-Intestinal Serious Adverse Events (GI-SAE)</measure>
    <time_frame>up to 19 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence and duration of hospital stay due to adverse events related to trial drug administration</measure>
    <time_frame>up to 19 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of an additional visit at physician due to gastro-intestinal adverse event (GI-AE)</measure>
    <time_frame>up to 19 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 19 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events related to trial drug</measure>
    <time_frame>up to 19 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">390</enrollment>
  <condition>Pharyngitis</condition>
  <arm_group>
    <arm_group_label>Meloxicam low &amp; Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Meloxicam high &amp; Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Naproxen sodium &amp; Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam low</intervention_name>
    <arm_group_label>Meloxicam low &amp; Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam high</intervention_name>
    <arm_group_label>Meloxicam high &amp; Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen sodium</intervention_name>
    <arm_group_label>Naproxen sodium &amp; Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam placebo low</intervention_name>
    <arm_group_label>Meloxicam high &amp; Placebo</arm_group_label>
    <arm_group_label>Naproxen sodium &amp; Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meloxicam placebo high</intervention_name>
    <arm_group_label>Meloxicam low &amp; Placebo</arm_group_label>
    <arm_group_label>Naproxen sodium &amp; Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen sodium placebo</intervention_name>
    <arm_group_label>Meloxicam low &amp; Placebo</arm_group_label>
    <arm_group_label>Meloxicam high &amp; Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged 18 years or above

          -  Ambulatory patients

          -  Start of symptoms within the previous 24 hours

          -  Patients suffering from acute non bacterial pharyngitis or pharyngo-tonsillitis
             diagnostic, under the following criteria:

               -  spontaneous pharyngeal pain presence greater than 35 mm on a 100 mm visual analog
                  scale (VAS)

               -  Pharyngeal pain presence on swallowing greater than 35 mm on a 100 mm VAS

               -  Pharyngeal and/or amygdaline hyperemia

               -  Absence of purulent plaques

               -  Negative test for β-haemolytic Streptococcus on pharyngeal exudate

          -  Therapy with NSAID (Non-Steroid Anti-Inflammatory Drug) is required or recommended

          -  Patient's informed consent in accordance with local law and ICH GCP (International
             Conference of Harmonization Good Clinical Practice) , before inclusion into the the
             trial

        Exclusion Criteria:

          -  Suspicion of acute pharyngitis or pharyngo-tonsillitis from bacterial origin by
             clinical criteria; Several impairment of patients condition, indicated by one or more
             or the following symptoms:

               -  Extremely rapid onset of clinical picture

               -  Very high fever (&gt;38.5°C)

               -  Severe pharyngeal pain

               -  Cervical adenopathy

               -  Intense headache

               -  Purulent pharyngeal plaques, evidence of peritonsillar abscess or phlegmon

          -  Known or suspected hypersensitivity to the trial drug or NSAIDs

          -  Positive test for β-haemolytic Streptococcus on pharyngeal exudate

          -  Therapy with antimicrobial agents prior to start of the trial

          -  Chronic infections

          -  Infectious mononucleosis

          -  Active peptic ulcer within the past 6 months

          -  Pregnancy or breast feeding precaution: attention should be drawn to reports that
             NSAIDs were reported to decrease the efficacy of intrauterine devices

          -  Asthma, nasal polyps, angioneurotic edema or urticaria following the administration of
             aspirin or NSAIDs

          -  Concomitant treatment with anti-coagulants (including heparin), lithium or
             methotrexate

          -  Concomitant administration of other NSAIDs (including high-dose &gt; 1500 mg at day
             aspirin) or analgesic agents

          -  Administration of any NSAID during the last three days or analgesics 6 hours prior to
             the first administration of the trial drug

          -  Present treatment or treatment within the last two months with corticosteroids

          -  Historically know of impaired renal function (serum urea &gt; 125 % of the upper limit of
             normal range; serum creatinine &gt; 150 % of the upper limit of normal range)

          -  Historically know of severe liver injury (alanine amino transferase ALAT &gt; 2 x the
             upper normal range limit or aspartate amino transferase ASAT &gt; 2 x the upper normal
             range limit)

          -  Historically know of hematological disorder (platelet count &lt; 100,000/mm3, leucocyte
             count &lt; 3,000/mm3)

          -  Participation in another clinical trial during this study or during the previous month

          -  Previous participation in this trial

          -  Patient unable to comply with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 4, 2014</study_first_submitted>
  <study_first_submitted_qc>July 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 7, 2014</last_update_submitted>
  <last_update_submitted_qc>July 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharyngitis</mesh_term>
    <mesh_term>Tonsillitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Meloxicam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

